NASDAQ:NEUP

Neuphoria Therapeutics Q2 2025 Earnings Results & Report

Neuphoria Therapeutics logo
$2.29 +0.02 (+0.88%)
Closing price 03:59 PM Eastern
Extended Trading
$2.28 -0.01 (-0.44%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neuphoria Therapeutics beat analyst earnings expectations in its Q2 2025 results, released February 14, 2025. The company reported EPS of -$1.23 versus the -$2.01 consensus estimate, while revenue was $660 billion.

Earnings Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call
7:00 AM ET

Neuphoria Therapeutics EPS Results

Actual EPS
-$1.23
Consensus EPS
-$2.01
Beat/Miss
Beat by +$0.78
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 6 quarters

Neuphoria Therapeutics Revenue Results

Actual Revenue
$660 billion
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Neuphoria Therapeutics Q2 2025 Earnings FAQ

Neuphoria Therapeutics (NASDAQ:NEUP) reported earnings of -$1.23 per share for Q2 2025, beating the consensus estimate of -$2.01. The report was announced on Friday, February 14, 2025.

Neuphoria Therapeutics reported revenue of $660 billion for Q2 2025.

Neuphoria Therapeutics Earnings Headlines

Under 3 cents a night
Bill Poulos's Black Friday deal: a full year of the Instant Scanner for $7, one payment. The regular price is $247, about a dollar a night. With roughly 250 trading nights a year, that's 2.8 cents a night to have nearly a thousand of America's biggest stocks checked, with exact buy prices on whatever qualifies. No re-bills and nothing to install. At $7, the only question is whether you get around to it.tc pixel
Neuphoria Therapeutics Inc Ordinary Shares NEUP
Neuphoria Therapeutics Inc (NEUP)
See More Neuphoria Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Neuphoria Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Neuphoria Therapeutics and other key companies, straight to your email.

About Neuphoria Therapeutics

Neuphoria Therapeutics (NASDAQ:NEUP), Inc. is a clinical-stage biopharmaceutical company focused on developing investigational treatments for neurological and psychiatric conditions.

The company’s work centers on advancing drug candidates intended to address needs in brain health. Its products remain in development rather than being established, marketed therapies.

Publicly available information about Neuphoria’s specific development programs, operating geographies and leadership is limited, so no additional details are included here.

View Neuphoria Therapeutics Profile